全文获取类型
收费全文 | 47494篇 |
免费 | 3315篇 |
国内免费 | 941篇 |
专业分类
耳鼻咽喉 | 212篇 |
儿科学 | 519篇 |
妇产科学 | 508篇 |
基础医学 | 4307篇 |
口腔科学 | 495篇 |
临床医学 | 4273篇 |
内科学 | 3750篇 |
皮肤病学 | 670篇 |
神经病学 | 8315篇 |
特种医学 | 1585篇 |
外国民族医学 | 291篇 |
外科学 | 2487篇 |
综合类 | 6967篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 3521篇 |
眼科学 | 409篇 |
药学 | 7888篇 |
8篇 | |
中国医学 | 3230篇 |
肿瘤学 | 2312篇 |
出版年
2024年 | 54篇 |
2023年 | 498篇 |
2022年 | 737篇 |
2021年 | 1231篇 |
2020年 | 1119篇 |
2019年 | 1389篇 |
2018年 | 1543篇 |
2017年 | 1286篇 |
2016年 | 1159篇 |
2015年 | 1078篇 |
2014年 | 5685篇 |
2013年 | 5008篇 |
2012年 | 3654篇 |
2011年 | 3661篇 |
2010年 | 4666篇 |
2009年 | 4475篇 |
2008年 | 2700篇 |
2007年 | 1605篇 |
2006年 | 1308篇 |
2005年 | 1016篇 |
2004年 | 903篇 |
2003年 | 762篇 |
2002年 | 599篇 |
2001年 | 589篇 |
2000年 | 480篇 |
1999年 | 454篇 |
1998年 | 385篇 |
1997年 | 397篇 |
1996年 | 393篇 |
1995年 | 308篇 |
1994年 | 257篇 |
1993年 | 224篇 |
1992年 | 198篇 |
1991年 | 186篇 |
1990年 | 185篇 |
1989年 | 131篇 |
1988年 | 130篇 |
1987年 | 136篇 |
1986年 | 98篇 |
1985年 | 164篇 |
1984年 | 164篇 |
1983年 | 129篇 |
1982年 | 136篇 |
1981年 | 90篇 |
1980年 | 101篇 |
1979年 | 74篇 |
1978年 | 44篇 |
1977年 | 44篇 |
1976年 | 42篇 |
1975年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
21.
22.
23.
目的:建立大黄特征化学成分和抗氧化活性相关联的二维指纹图谱,研究大黄抗氧化活性物质。方法:利用高效液相多检测器联用的抗氧化活性成分在线检测体系,对大黄中化学成分进行检测,共鉴定出大黄中化学成分15种;其中8种具有抗氧化活性;然后采用清除效率为指标对各活性成分的抗氧化活性进行评价。结果:结果发现化合物葡萄糖紫丁香酸、腺嘌呤、没食子酸、儿茶素或表儿茶素、双花母草素、2-O-桂皮酰-没食子酰葡萄糖等具有较强的清除ABTS·+的活性,而蒽醌类成分对ABTS·+的清除作用较弱。结论:采用HPLC-ABTS-DAD-Q-TOF/MS对大黄中的抗氧化活性成分进行快速分析鉴定,初步阐明大黄在抗氧化环节起作用的效应物质。 相似文献
24.
《Research in social & administrative pharmacy》2022,18(11):3988-3994
BackgroundScarce data exists regarding United States (US) national-level work productivity loss among adults with Multiple Sclerosis (MS).ObjectiveTo address this significant knowledge gap, we examined the national-level productivity loss among adults (18≤ age ≤64 years) with MS compared to propensity score matched non-MS controls.MethodsWe adopted a retrospective, cross-sectional, matched cohort study design with pooled data from alternate years (2005/2007/2009/2011/2013/2015) of the Medical Expenditure Panel Survey (MEPS). We included adults who were employed and alive during the calendar year. Clinical Classification System code of “80” was used to identify individuals with MS. We matched adults with MS to non-MS adults utilizing propensity scores generated based on age, gender, and race/ethnicity using a greedy matching algorithm (8:1-digit matching). Missed workdays measured productivity loss of MEPS respondents. We selected Negative Binomial Regression (NBR) analysis as the count data model for this study. Analyses were conducted using SAS 9.4 and STATA 15.0 and accounted for the complex survey design of MEPS to generate US national-level estimates.ResultsThe final propensity-score matched sample consisted of 104 and 312 (unweighted) adults with and without MS, respectively. US national-level mean [Standard Error (SE)] annual missed workdays among individuals with MS [8.94 (SE:1.59)] was significantly higher (p = 0.001) compared to propensity score matched non-MS controls [3.15 (SE:0.40)]. After adjusting for several factors, NBR showed an approximately two-fold higher rate of missed work days among individuals with MS compared to propensity score matched non-MS controls (Incidence Rate Ratio: 1.98, 95% Confidence Interval: 1.18–3.33). Severity of pain, marital status, region, and hypertension also negatively impacted work productivity in this sample.ConclusionsIndividuals with MS in the US experience significantly higher productivity loss compared to propensity score matched non-MS controls. Interventions (e.g., improved management of MS symptoms) are warranted to reduce productivity loss among individuals with MS. 相似文献
25.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
26.
《Journal de Mycologie Médicale》2020,30(3):100974
To determine fungal species distribution of interdigital intertrigo among seafarers in Dakar, Senegal, a cross-sectional study was carried out from May to August 2017 among seafarers clinically diagnosed with interdigital intertrigo. A questionnaire was filled to each patient before sampling the affected folds and transporting to Aristide Le Dantec University Hospital where mycological analyses were realized. Species identification by MALDI-TOF MS was performed in Marseille, France. In total, 169 men (21–66 years) were included. Few of them (3%) had a high level of education and the duration of the mycosis exceed 10 years for 88% of patients. Direct microscopic examination (ME) was positive in 34.3%. Among samples with positive ME, 58.6% had positive culture. An overall incidence of 30.2% was found. Patients with confirmed cases aged between 28 and 66 years. Among them, those between 36–50 years were predominant (52.9%). Those with a high level of education were less representative (2%). For 52.1% of patients, the duration of the mycosis was superior to 10 years. Furthermore, 57% of cases were significantly associated with other types of tinea pedis and/or onychomycosis (P = 0.03). Culture was positive in 23.7% isolating 43 strains successfully identified at the species level by MALDI-TOF MS for 31 isolates: 20 Candida and 11 dermatophytes. The rest was identified only at the genus level belonged to Fusarium. In definitive, MALDI-TOF MS could be a useful tool for routine and fast identification of dermatophytes, yeasts and NDFF in clinical mycology laboratories. 相似文献
27.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
28.
29.
目的:评定LC-MS/MS法测定人血浆中布康唑浓度的不确定度。方法:分析测定过程中不确定度的来源,包括对照品的称量、仪器误差、标准溶液的配制、含药血浆样品的配制、血浆样品的处理、标准曲线的拟合、基质效应、重复性等,评定各来源分量的不确定度,计算合成不确定度和扩展不确定度。结果:人血浆中低(60.0 pg·mL-1)、中(600.0 pg·mL-1)、高(6 400.0 pg·mL-1)浓度布康唑的扩展不确定度分别为5.62,63.90,626.26 pg·mL-1(k=2,P=95%)。结论:LC-MS/MS法测定人血浆中布康唑浓度的不确定度主要由基质效应、血浆样品的处理(提取回收率),仪器误差、重复性(精密度)引入。 相似文献
30.
《Revue neurologique》2022,178(8):812-816
IntroductionAs an immune-mediated disease of the central nervous system, multifaceted aspects of a humoral immune response are widely described during multiple sclerosis (MS). However, the prevalence of different auto-antibodies, such as antinuclear antibodies (ANA), during MS is very variable and their clinical relevance remains controversial. Our aim was to evaluate the prevalence and clinical correlations of ANA positivity in South Tunisian MS patients.Material and methodsWe performed ANA screening using indirect immunofluorescence (IIF) on HEp-2 cells (Biosystems®) in 82 MS patients. For ANA positive samples (titer ≥1/160), anti-ds-DNA detection (IIF on Crithidia luciliae (Biosystems®)) and extractable nuclear antigen typing (immunodot (Euroimmun®)) were performed.ResultsANA were positive in 35/82 MS patients (42.7%). The titer was ≥ 1/320 in 16/35 patients. The antigenic specificity of ANA was identified in 7/35 patients. None of the patients had extra-neurological manifestations. No correlation was found between ANA and age, gender, MS course, disease duration, disability, annual relapse rate nor IgG index. ANA positivity was more frequent in patients with IgG oligoclonal bands (OCB) (47.1%) than in patients without IgG OCB (16,6%) (p = 0.049). Regarding disease activity, ANA positivity was significantly more frequent in patients with relapse (52.6%) than in patients in remission (25.9%) (p = 0.031).ConclusionOur results showed that ANA positivity in MS disease is not rare. This positivity was not associated with clinical expression of any connective tissue disease. ANA occurrence in MS was associated with IgG OCB+ profile and relapsing status, probably reflecting an ongoing immune dysregulation. 相似文献